| 0 (0%) | 11-11 15:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.59 | 1-year : | 7.93 |
| Resists | First : | 5.64 | Second : | 6.78 |
| Pivot price | 5.01  |
|||
| Supports | First : | 3.78 | Second : | 3.15 |
| MAs | MA(5) : | 4.17 |
MA(20) : | 5.28 |
| MA(100) : | 5.67 |
MA(250) : | 4.71 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 18.8 |
D(3) : | 13.1 |
| RSI | RSI(14): 39.6 |
|||
| 52-week | High : | 7.36 | Low : | 2.41 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SLDB ] has closed above bottom band by 31.4%. Bollinger Bands are 101.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.22 - 4.25 | 4.25 - 4.28 |
| Low: | 3.95 - 3.98 | 3.98 - 4.01 |
| Close: | 4.11 - 4.16 | 4.16 - 4.2 |
Tue, 11 Nov 2025
Solid Biosciences (Nasdaq: SLDB) in Jefferies, Piper Sandler fireside chats with webcasts - Stock Titan
Mon, 10 Nov 2025
Tick level data insight on SLDB volatility - July 2025 PostEarnings & Detailed Earnings Play Strategies - newser.com
Sun, 09 Nov 2025
Is SLDB stock a good choice for value investors - Forecast Cut & Daily Risk Controlled Trade Plans - newser.com
Thu, 06 Nov 2025
Solid Biosciences (NASDAQ: SLDB) SGT-003 gets UK ILAP Innovation Passport for Duchenne - Stock Titan
Thu, 06 Nov 2025
SLDB: Citigroup Lowers Price Target but Maintains Buy Rating | S - GuruFocus
Wed, 05 Nov 2025
JP Morgan Adjusts Price Target for Solid Biosciences (SLDB) | SL - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 78 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 106 (%) |
| Shares Short | 9,570 (K) |
| Shares Short P.Month | 9,940 (K) |
| EPS | -2.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.32 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.4 % |
| Return on Equity (ttm) | -68.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.24 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -123 (M) |
| Levered Free Cash Flow | -73 (M) |
| PE Ratio | -1.62 |
| PEG Ratio | 0 |
| Price to Book value | 1.35 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|